Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris

Arch Dermatol. 2003 Mar;139(3):337-9. doi: 10.1001/archderm.139.3.337.

Abstract

Background: Flagellate hyperpigmentation is a well-documented complication of systemic bleomycin sulfate therapy when using doses of 100 U or more as an antineoplastic agent. Two cases occurred after using systemic doses from 15 to 30 U injected intravenously or intrapleurally; however, it has not been described as a complication following intralesional treatment of verruca plantaris.

Observations: We report a case of flagellate hyperpigmentation after intralesional injection of 14 U of bleomycin for verrucae plantaris and review the literature associated with this cutaneous complication.

Conclusions: Flagellate hyperpigmentation from extremely low doses of intralesional bleomycin is a previously undescribed complication. Although the mechanisms of reaction are not clearly understood, the clinician should be mindful of this uncommon complication.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Abdomen
  • Adult
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / adverse effects*
  • Bleomycin / administration & dosage
  • Bleomycin / adverse effects*
  • Female
  • Foot Dermatoses / drug therapy*
  • Foot Dermatoses / pathology
  • Humans
  • Hyperpigmentation / chemically induced*
  • Hyperpigmentation / pathology
  • Injections, Intralesional
  • Warts / drug therapy*
  • Warts / pathology

Substances

  • Antibiotics, Antineoplastic
  • Bleomycin